{
    "clinical_study": {
        "@rank": "134642", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "multiple doses BI 187004"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental", 
                "description": "multiple doses BI 187004 + multiple doses metformin"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "arm_group_type": "Experimental", 
                "description": "multiple doses metformin"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate bioavailability of BI 187004 and of metformin after concomitant multiple oral\n      administration of 240 mg BI 187004 q.d. and 1000 mg metformin b.i.d. in comparison to BI\n      187004 and metformin given alone."
        }, 
        "brief_title": "Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy male subjects\n\n          2. Subjects must be able to understand and comply with study requirements\n\n          3. Age of 18 to 50 years\n\n          4. Body mass index (BMI) of 18.5 to 29.9 kg/m2\n\n        Exclusion criteria:\n\n          1. Any finding in the medical examination (including BP, pulse rate (PR) or ECG) is\n             deviating from normal and judged as clinically relevant by the investigator\n\n          2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg\n             or diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside\n             the range of 50 to 90 bpm\n\n          3. Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          4. Any evidence of a concomitant disease judged as clinically relevant by the\n             investigator\n\n          5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          6. Surgery of the gastrointestinal tract that could interfere with kinetics of the trial\n             medication (except appendectomy and simple hernia repair)\n\n          7. Diseases of the central nervous system (such as epilepsy), other neurological\n             disorders or psychiatric disorders"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109679", 
            "org_study_id": "1307.7", 
            "secondary_id": "2013-004628-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment C", 
                "description": "multiple doses metformin given as tablet", 
                "intervention_name": "metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment A", 
                "description": "multiple doses BI 187004 given as tablets", 
                "intervention_name": "BI 187004", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "description": "multiple doses BI 187004 given as tablets", 
                "intervention_name": "BI 187004", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "description": "multiple doses metformin given as tablet", 
                "intervention_name": "metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Biberach", 
                    "country": "Germany"
                }, 
                "name": "1307.7.1 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects (an Open-label, Randomised, Two-sequence Crossover Study)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t) for BI 187004", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours postdose"
            }, 
            {
                "measure": "AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t) for metformin", 
                "safety_issue": "No", 
                "time_frame": "up to 12 hours postdose"
            }, 
            {
                "measure": "Cmax,ss (Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t) for BI 187004", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours postdose"
            }, 
            {
                "measure": "Cmax,ss (Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t) for metformin", 
                "safety_issue": "No", 
                "time_frame": "up to 12 hours postdose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109679"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}